Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review

INTRODUCTION

JAK inhibitors are small-molecule agents that block the signalling of several cytokines involved in the pathogenesis of alopecia areata (AA), notably interferon-γ and interleukin-15, which activate and perpetuate CD8⁺ cytotoxic T cells, responsible for autoimmune inflammation against the hair follicle.^[1] Both topical and systemic formulations of JAK inhibitors have been utilized in the management of alopecia areata.^[2] A 2014 case report was the first to demonstrate that the JAK inhibitor tofacitinib (Xeljanz®) could successfully treat alopecia areata. Since then, multiple studies have confirmed the efficacy of JAK inhibitors in promoting hair regrowth in this condition.^[3] The FDA-approved oral JAK inhibitors for severe alopecia areata include baricitinib and deuruxolitinib, for adults >18 years, ritlecitinib inhibitor for adults and adolescents ≥12 years.^[4] We hereby discuss in detail the mechanism of action of individual JAK inhibitors and the efficacy data of the same.

PATHOGENESIS OF ALOPECIA AREATA

The hair follicle possesses a relative state of immune privilege, and alopecia areata (AA) is characterized by a breakdown of this privilege [Figure 1]. In particular, anagen hair follicles, especially those involved in pigment production, become targets of inflammatory cell infiltration.^[5] Cytotoxic CD8⁺ NKG2D⁺ T cells have been identified as key mediators in the pathogenesis of AA. Upregulation of interleukin-15 (IL-15) within the hair follicle microenvironment contributes to the loss of immune privilege by promoting the recruitment and activation of CD8⁺ NKG2D⁺ T cells, which subsequently produce interferon-gamma (IFN-γ).^[6] Genome-wide association studies have revealed associations between AA and multiple genes regulating regulatory T-cell activity and cytokine signaling, including IL-2/IL-21, cytotoxic T-lymphocyte–associated antigen 4 (CTLA4), human leukocyte antigen (HLA) region genes, and IL-2 receptor alpha (IL-2RA).^[7] While genetic predisposition is evident, the role of environmental factors in disease initiation remains uncertain.^[7]

Close

Figure 1:

Depicts the immunopathogenesis of alopecia areata [created using Grok AI].

Export to PPT

The Janus kinase (JAK) family comprises four intracellular tyrosine kinases: JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2), which interact with type I and II cytokine receptors to mediate downstream signal transduction. These kinases regulate fundamental cellular processes, including proliferation, migration, differentiation, and apoptosis.^[8] JAKs are integral to hematopoiesis, immune regulation, and host defense mechanisms. Cytokine signaling through IL-15, IFN-γ, and other cytokines implicated in AA (e.g., IL-2, IL-7, IL-13, and IL-21) occurs via the JAK–signal transducer and activator of transcription (STAT) pathway.^[9]

In AA, IFN-γ promotes IL-15 production in hair follicles through JAK1/2 signaling, while IL-15 in turn stimulates IFN-γ release by T cells via JAK1/3 signaling, establishing a positive feedback loop that amplifies perifollicular inflammation [Table 1].^[10] These insights have identified JAK inhibitors as promising therapeutic agents in the management of AA.

OFF LABEL JAK STAT INHIBITORS

Other JAK inhibitors that have been used off-label for AA include the first-generation agents tofacitinib and ruxolitinib.

These two off-label molecules are discussed in detail. More recently, a range of selective second-generation JAK inhibitors has been developed, such as upadacitinib, brepocitinib, ritlecitinib, abrocitinib, jaktinib, deucravacitinib, ifidancitinib, and delgocitinib have been tried with less evidence.^[22] Table 1 provides an overview of JAK-STAT inhibitors reported in the literature for the treatment of AA.

Tofacitinib

Tofacitinib, a pan JAK1/3>2, TYK inhibitor, has been used in topical and oral formulations [Table 2] for alopecia areata. The recommended dose of tofacitinib ranges from 2.5 mg to15 mg once daily for AA. The oral bioavailability of ~74%, and the drug is primarily metabolized in the liver via CYP3A4, with a minor contribution from CYP2C19, producing inactive metabolites. Elimination occurs mainly through the urine (~70%) and partially via feces (~30%), with a half-life of ~3 hours, supporting a twice-daily dosing regimen. Steady-state concentrations are reached within 24–48 hours, and pharmacokinetics are generally dose-proportional, though co-administration with CYP3A4 modulators can alter exposure. As a pan JAK inhibitor, it inhibits the inflammatory cascade linked with AA, such as interleukin (IL)-2, IL-4, IL-7, IL-9, IL-15, IL-21, and interferon (IFN)-γ [Figure 2].^[23]

Table 2: Summary of JAK inhibitors, dosing schedule and mechanism of action in AA

JAK inhibitors	Mechanism of Action	Route	Dosing Regimens	Efficacy
Baricitinib	JAK1/JAK2 inhibitor	Oral	4 mg or 2 mg once daily	Phase 3 BRAVE-AA trials show ~35–40% SALT ≤20 at 36 weekswith 4 mg; ~20–25% with 2 mg. Mean SALT improvement~45–50%.
Tofacitinib	JAK1/JAK2/JAK3/TYK inhibitor	Oral	5 mg twice daily; 10 mg twice daily; 10–25 mg split twice daily	Real-world studies report 30–60% mean SALT improvement;up to 70% regrowth in responsive patients. Higher doses moreeffective but relapse common.
Topical			2% twice daily	Limited evidence—10–20% SALT improvement; more effectivefor eyebrows/patchy AA.
Ruxolitinib	JAK1/JAK2 inhibitor	Oral	20 mg twice daily; 5–15 mg twice daily; 10–25 mg twice daily	Small cohorts show 50–75% mean SALT improvement at 3–6months; efficacy similar to tofacitinib in some series.
Topical			0.6% twice daily; 1% twice daily; 1.5% twice daily	Topical formulations show modest benefit, ~15–25% SALTimprovement; best responses in eyebrow/limited AA.
Ritlecitinib	JAK3/TEC inhibitor	Oral	200 mg once daily for 4 weeks, then 50 mg once daily for 20 weeks; 50 mg, 30 mg, or 10 mg once daily	ALLEGRO trials: ~25–30% SALT ≤20 at week 24 with 50 mg;mean SALT improvement ~40%. Stronger responses in severeAA with continuous use.
Brepocitinib	TYK2/JAK1 inhibitor	Oral	60 mg once daily for 4 weeks, then 30 mg once daily for 20 weeks	Phase 2 data show ~50% SALT improvement; ~25–30% achieveSALT ≤20. Efficacy comparable to ritlecitinib.
Upadacitinib	JAK1 inhibitor	Oral	30 mg daily	Limited AA-specific data; small studies show 35–50% SALTimprovement at 24 weeks, better responses at higher doses.
Abrocitinib	JAK1 inhibitor	Oral	200 mg daily; 100 mg or 200 mg once daily	Early reports/real-world data suggest 30–40% SALTimprovement, but robust AA-specific trials are limited.
Ifidancitinib	JAK1/JAK3 inhibitor	Topical	0.5% or 0.1% twice daily	-
Delgocitinib	JAK1/JAK2/JAK3/TYK2 inhibitor	Topical	30 mg/g twice daily	-

BRAVE: Baricitinib Alopecia Areata Clinical Program; JAK: Janus kinase inhibitors, AA: Alopecia areata, TYK: Tyrosine kinase inhibitor, SALT: Severity of alopecia tool.

Close

Figure 2:

(a) Depicts the baseline, (b) Complete resolution of alopecia areata after 9 months of tofacitinib.

Export to PPT

Studies using tofacitinib 5 mg twice daily have shown encouraging results in alopecia areata. In an open-label study of 66 patients, 64% responded after 3 months, with similar outcomes across subtypes.^[23] A 2019 retrospective study of 63 patients (73% with alopecia universalis) reported complete regrowth in 40%, partial regrowth in 43%, and minimal regrowth in 12% after 6 months, with only 5% nonresponders. In comparison, regimens escalating up to 10 mg twice daily (as in Jabbari et al.) achieved >50% regrowth in 67% of 12 patients over 6–12 months, with median SALT score improvements of 70% in patch-type AA and 68% in ophiasis, but substantially lower in alopecia totalis (11.8%) and universalis (10.5%).^[24] In adults, as per a systematic review of 12 studies, out of 346 patients, 288 patients were on oral tofacitinib, and 58 were on oral ruxolitinib, and a 50% reduction in SALT score was seen in 66% of cases. Recurrence of AA was seen in 74% of the patients within 3 months after withdrawal of therapy. ^[25]

As per the retrospective study by Huang et al. and Jerjen et al. in 11 preadolescent populations, 64% of the cases showed a 50% improvement in the SALT score earlier with oral tofacitinib alone, and 63.6% showed a 50% reduction in the SALT score in the latter study with oral tofacitinib and oral minoxidil.^[26,27] These data were in concordance with the results seen in the current series, but in previous studies, less than 50% of the cases of AT and AU were recruited. As per Indian data, a case report by Bhokare et al. showed that a young boy with therapy-resistant patch type AA responded to tofacitinib within 2 months and that complete hair growth was seen in 6 months.^[28]

OFF LABEL TOPICAL JAK INHIBITORS IN AA

Topical formulations include tofacitinib, ruxolitinib, ifidancitinib, and deucravacitinib. Topical formulations have also been used for eyelash and facial hair regrowth, with a case series (n = 119) showing complete regrowth in 41% of eyebrows and 46% of eyelashes.^[31] In a review of 136 instances of topical JAK inhibitor (JAKi) therapy for alopecia areata, the vast majority were administered as monotherapy (135/136, 99.3%), with only one case involving combination therapy. Tofacitinib was the most frequently used agent (43.7%), followed by ruxolitinib (41.5%) and delgocitinib (14.8%). Treatment duration was reported in 107 cases, with a mean of 142.6 days (range: 28–330 days). SALT scores were available in 39% of cases, showing an average reduction of 24.9% from baseline, and 23.5% of cases achieved ≥50% improvement (SALT50). Follow-up data on disease recurrence were limited (11%), with 2 of 15 patients (13.3%) experiencing relapse at a mean of 2.3 months. Concurrent therapy was not documented. Adverse events were infrequent (3.7%), limited to scalp irritation (4 cases) and folliculitis (1 case), with no treatment discontinuations, indicating that topical JAKi therapy is generally well tolerated with modest efficacy.^[32]

ADVERSE EVENTS

The FDA has issued a black box warning for this class based on safety data from tofacitinib studies in rheumatoid arthritis. In dermatology, oral JAK1 inhibitors (abrocitinib, upadacitinib), the JAK1/2 inhibitor baricitinib, the TYK2 inhibitor deucravacitinib, and topical ruxolitinib are currently used, each with distinct safety profiles. Clinical trial data in dermatology show low rates of serious adverse events, including venous thromboembolism (0–0.5%), cardiovascular events (0–1.2%), serious infections (0.4–4.8%), nonmelanoma skin cancer (0–0.9%), and other malignancies (0–0.7%), with most affected patients having pre-existing risk factors. Common side effects of oral JAK inhibitors include upper respiratory infections, nasopharyngitis, nausea, headache, and acne. Dermatologists are advised to assess baseline patient risk factors and implement appropriate screening and laboratory monitoring when initiating therapy with JAK inhibitors. JAK 2 inhibitors can also cause anemia, lymphopenia, neutropenia, thrombocytopenia, hyperlipidemia, and creatine kinase elevations.^[33]

WHEN TO CONSIDER JAKi TREATMENT OF AA, AND OPTIMIZING EFICACY

Clinical trials of JAK inhibitors have primarily included adolescents and adults with 50–100% scalp hair loss of 6 months to 10 years’ duration. In practice, treatment may also be considered for less severe scalp involvement, eyebrow/eyelash loss, refractory disease, significant psychosocial impact, or diffuse positive hair pull test, and even for episodes longer than 10 years. Trial analyses have identified two key factors influencing efficacy: duration of severe hair loss, with treatment within the first 3–4 years showing better outcomes, and presence of existing scalp hair, which predicts greater response compared to near-total hair loss.^[34]

TAPERING of JAK INHIBITORS (AUTHOR’S EXPERIENCE)

JAK inhibitor tapering is individualized, as no standardized guideline exists, and decisions are based on clinical stability, disease severity, and relapse risk. In general, tapering should be attempted only after sustained remission for at least 6–12 months, with close monitoring every 4–8 weeks. The most commonly used approach involves stepwise dose reduction, beginning with decreasing the dose from 5 mg twice daily to 5 mg once daily, or equivalently from 10 mg once daily to 5 mg once daily. If the disease remains controlled for 2–3 months, the dosing interval may be extended to alternate-day administration before eventual discontinuation. In patients with a history of severe disease, rapid progression, or frequent relapses, a slower or more conservative taper is preferred.^[35]

This may include gradually reducing the number of weekly doses (e.g., from daily dosing to 3–4 days per week) over several months before complete withdrawal. Throughout tapering, routine laboratory monitoring (CBC, liver enzymes, lipid profile) every three months, along with disease-specific clinical scores, is essential. Tapering should be avoided in patients with recent disease activity, remission lasting less than six months, or those dependent on tofacitinib as the anchor drug. If a flare occurs, the prior effective dose should be reinstated for stabilization before considering a slower tapering strategy.

LONG TERM SAFETY AND SUSTAINED MAINTENANCE OF EFFICACY

The risk of relapse after tapering or discontinuing tofacitinib is significant, particularly in alopecia areata. Relapse is commonly reported in 50–80% of patients after dose reduction or discontinuation, reflecting the drug’s short half-life and rapid loss of immune modulation.^[36] Preventing relapse and sustaining the therapeutic effect of tofacitinib in alopecia areata requires a combined strategy of prolonged remission, gradual tapering, adjunctive maintenance therapies, and close monitoring. Adjunctive maintenance options, including topical corticosteroids and intralesional corticosteroids for focal patches, and in multifocal and extensive cases, systemic therapy is preferred. Short-term mini-pulse oral steroids, azathioprine, and methotrexate may be considered in high-risk or extensive cases. If relapse occurs to the baseline, re-escalation to the last effective dose of tofacitinib and targeted local therapies often restores control. In individuals with severe phenotypes or repeated relapses, long-term low-dose maintenance therapy may be required to sustain regrowth and prevent disease recurrence; however, long-term safety in dermatological indications has not been explored.

A comprehensive safety analysis of JAK inhibitors in immune-mediated rheumatological diseases included 82 studies (selected from 973 screened), encompassing 66,159 patients exposed to JAK inhibitors, with approximately two-thirds of the studies being randomized controlled trials. The overall incidence of adverse events was 42.65 per 100 person-years, while serious adverse events occurred at a rate of 9.88 per 100 person-years. Specific safety outcomes included serious infections at 2.81 per 100 person-years, herpes zoster infection at 2.67 per 100 person-years, malignancy at 0.89 per 100 person-years, and major adverse cardiovascular events at 0.48 per 100 person-years. Importantly, all-cause mortality was not increased with JAK inhibitor therapy compared with placebo or active comparators (relative risk 0.72; 95% CI 0.40–1.28).^[37]

ROLE OF SWITCHING WITHIN JAK INHIBITORS

Switching JAK inhibitors (especially from tofacitinib → baricitinib or ritlecitinib → deuruxolitinib) represents a viable and often successful therapeutic strategy in refractory or relapsing alopecia areata, with real-world response rates of 60–80% in prior non-responders. This approach should be considered before abandoning the JAK inhibitor class entirely. Prospective studies are ongoing to confirm these findings.^[38]

CONCLUSION

JAK inhibitors represent a targeted, disease-modifying therapy for alopecia areata (AA) by disrupting the inflammatory cascade mediated by CD8⁺ NKG2D⁺ T cells, interferon-γ, and interleukin-15. Both oral and topical formulations have demonstrated efficacy in promoting hair regrowth across AA subtypes, including patchy, totalis, and universalis forms.

FDA-approved oral agents such as baricitinib, deuruxolitinib, and ritlecitinib, that have shown significant reductions in SALT scores, with the highest responses observed in patients with shorter disease duration and residual scalp hair at treatment initiation. Off-label therapies, including tofacitinib and ruxolitinib, also achieve meaningful regrowth, though relapse after discontinuation is common. Topical JAK inhibitors offer modest efficacy and a favorable safety profile, particularly for eyebrows and eyelashes.